There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Aptose Biosciences (APTO – Research Report), Harmony Biosciences Holdings (HRMY – Research Report) and Atara Biotherapeutics (ATRA – Research Report) with bullish sentiments.
Aptose Biosciences (APTO)
In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Aptose Biosciences, with a price target of $12.00. The company’s shares closed last Wednesday at $3.32, close to its 52-week low of $2.91.
According to TipRanks.com, Tenthoff is a 4-star analyst with an average return of
Aptose Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $17.00.
See the top stocks recommended by analysts >>
Harmony Biosciences Holdings (HRMY)
Mizuho Securities analyst Graig Suvannavejh reiterated a Buy rating on Harmony Biosciences Holdings on September 19 and set a price target of $54.00. The company’s shares closed last Wednesday at $37.35.
According to TipRanks.com, Suvannavejh has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Harmony Biosciences Holdings is a Strong Buy with an average price target of $60.29, implying a 62.9% upside from current levels. In a report issued on September 6, Berenberg Bank also maintained a Buy rating on the stock with a $59.00 price target.
Atara Biotherapeutics (ATRA)
In a report issued on September 19, Salim Syed from Mizuho Securities maintained a Buy rating on Atara Biotherapeutics, with a price target of $31.00. The company’s shares closed last Wednesday at $1.76, close to its 52-week low of $1.25.
According to TipRanks.com, Syed is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on Atara Biotherapeutics is a Moderate Buy with an average price target of $20.10.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on APTO:
- Aptose to Present at the Cantor Global Healthcare Conference
- Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical
- Aptose Biosciences closes $3M investment by Hanmi
- Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- Aptose Biosciences price target lowered to $23 from $40 at RBC Capital
